Table 2.
Maintenance subcutaneous ustekinumab doses prescribed to study subjects.
| Ustekinumab dose 90mg | Ustekinumab dose 180mg |
|---|---|
| 12 weekly 1.9% (n = 1) | 8 weekly 1.9% (n = 1) |
| 8 weekly 64.2% (n = 34) | 4 weekly 17% (n = 9) |
| 6 weekly 7.5% (n = 4) | |
| 4 weekly 7.5% (n = 4) |